Considering a molecular therapeutic viewpoint, Relafen 750, designated naproxen sodium, showcases a compelling case study in NSAID treatment design. The mechanism of action primarily involves the inhibition of cyclooxygenase proteins, specifically COX-1 and COX-2, resulting in a decrease of prostaglandin formation, these cause pain and swelling . A

Relafen 750, chemically identified as naproxol, showcases a fascinating case study from a biochemical medicinal viewpoint. Its mechanism of alleviating inflammation involves the specific inhibition of cyclooxygenase-2 (COX-2), an enzyme crucial for the synthesis of prostanoids, potent regulators of inflammation and pain. Unlike older NSAIDs, Relafe